文献速递妇科

良性腹腔镜与机器人子宫切除术中腹腔镜下子宫骶韧带注射布比卡因:一项随机对照试验

Laparoscopic administration of bupivacaine at the uterosacral ligaments during benign laparoscopic and robotic hysterectomy: a randomized controlled trial.
PubMed 文献 · Am J Obstet Gynecol · 2023-07-31

本研究为单盲三臂随机对照试验,纳入180例良性腹腔镜或机器人子宫切除术患者,随机分为不注射、20 mL生理盐水或20 mL 0.25%布比卡因注射至子宫骶韧带。结果显示布比卡因组与对照组在24小时口服吗啡当量用量、疼痛评分、7天总阿片用量等方面均无显著差异。

要点

  • 腹腔镜下子宫骶韧带注射布比卡因未减少24小时及7天阿片用量。
  • 布比卡因组与对照组疼痛评分无显著差异,出院时疼痛评分有接近显著的趋势。
  • 术后24小时阿片用量增加的预测因素仅为麻醉恢复室阿片用量增加。

核心结论

  • 微创子宫切除术中腹腔镜下子宫骶韧带注射布比卡因未减少阿片用量或改变疼痛评分。

研究设计与样本

  • 单盲三臂随机对照试验,于2021年3月15日至2022年4月8日在学术医疗中心进行,最终纳入180例患者。

主要发现

  • 三组24小时口服吗啡当量用量无差异(P=.10)。
  • 三组疼痛评分、7天总口服吗啡当量用量、末次阿片使用日及肠功能恢复均无差异(P>.05)。
  • 布比卡因组出院时疼痛评分有接近显著的趋势。
  • 24小时阿片用量增加的预测因素仅为麻醉恢复室口服吗啡当量用量增加。
  • 7天阿片用量增加的预测因素包括当前吸烟、情绪障碍、既往腹腔镜史、估计失血量>200 mL及麻醉恢复室阿片用量增加。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Postoperative pain continues to be an undermanaged part of the surgical experience. Multimodal analgesia has been adopted in response to the opioid epidemic, but opioid prescribing practices remain high after minimally invasive hysterectomy. Novel adjuvant opioid-sparing analgesia to optimize acute postoperative pain control is crucial in preventing chronic pain and minimizing opioid usage. OBJECTIVE: This study aimed to determine the effect of direct laparoscopic uterosacral bupivacaine administration on opioid usage and postoperative pain in patients undergoing benign minimally invasive (laparoscopic and robotic) hysterectomy. STUDY DESIGN: This was a single-blinded, triple-arm, randomized controlled trial at an academic medical center between March 15, 2021, and April 8, 2022. The inclusion criteria were patients aged >18 years undergoing benign laparoscopic or robotic hysterectomy. The exclusion criteria were non-English-speaking patients, patients with an allergy to bupivacaine or actively using opioid medications, patients undergoing transversus abdominis plane block, and patients undergoing supracervical hysterectomy or combination cases with other surgical services. Patients were randomized in a 1:1:1 fashion to the following uterosacral administration before colpotomy: no administration, 20 mL of normal saline, or 20 mL of 0.25% bupivacaine. All patients received incisional infiltration with 10 mL of 0.25% bupivacaine. The primary outcome was 24-hour oral morphine equivalent usage (postoperative day 0 and postoperative day 1). The secondary outcomes were total oral morphine equivalent usage in 7 days, last day of oral morphine equivalent usage, numeric pain scores from the universal pain assessment tool, and return of bowel function. Patients reported postoperative pain scores, total opioid consumption, and return of bowel function via Qualtrics surveys. Patient and surgical characteristics and primary and secondary outcomes were compared using chi-square analysis and 1-way analysis of variance. Multiple linear regression was used to identify predictors of opioid use in the first 24 hours after surgery and total opioid use in the 7 days after surgery. RESULTS: Of 518 hysterectomies screened, 410 (79%) were eligible, 215 (52%) agreed to participate, and 180 were ultimately included in the final analysis after accounting for dropout. Most hysterectomies (70%) were performed laparoscopically, and the remainder were performed robotically. Most hysterectomies (94%) were outpatient. Patients randomized to bupivacaine had higher rates of former and current tobacco use, and patients randomized to the no-administration group had higher rates of previous surgery. There was no difference in first 24-hour oral morphine equivalent use among the groups (P=.10). Moreover, there was no difference in numeric pain scores (although a trend toward significance in discharge pain scores in the bupivacaine group), total 7-day oral morphine equivalent use, day of last opioid use, or return of bowel function among the groups (P>.05 for all). The predictors of increased 24-hour opioid usage among all patients included only increased postanesthesia care unit oral morphine equivalent usage. The predictors of 7-day opioid usage among all patients included concurrent tobacco use and mood disorder, history of previous laparoscopy, estimated blood loss of >200 mL, and increased oral morphine equivalent usage in the postanesthesia care unit. CONCLUSION: Laparoscopic uterosacral administration of bupivacaine at the time of minimally invasive hysterectomy did not result in decreased opioid usage or change in numeric pain scores.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Frost AS, Kohn JR, Le Neveu M, et al. Laparoscopic administration of bupivacaine at the uterosacral ligaments during benign laparoscopic and robotic hysterectomy: a randomized controlled trial. Am J Obstet Gynecol. 2023. PMID: 37531986. doi:10.1016/j.ajog.2023.07.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。